Neumora Therapeutics Inc Financials
Financial Health Signals
Neumora Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Neumora Therapeutics Inc generates $0.75 in operating cash flow (-$182.9M OCF vs -$243.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Neumora Therapeutics Inc (NMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Neumora Therapeutics Inc's EBITDA was -$262.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.5% from the prior year.
Neumora Therapeutics Inc reported -$243.8M in net income in fiscal year 2024. This represents a decrease of 3.3% from the prior year.
Neumora Therapeutics Inc earned $-1.53 per diluted share (EPS) in fiscal year 2024. This represents an increase of 57.9% from the prior year.
Neumora Therapeutics Inc held $142.1M in cash against $0 in long-term debt as of fiscal year 2024.
Neumora Therapeutics Inc had 162M shares outstanding in fiscal year 2024. This represents an increase of 1.8% from the prior year.
Neumora Therapeutics Inc invested $200.9M in research and development in fiscal year 2024. This represents an increase of 40.8% from the prior year.
NMRA Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $40.5M-33.2% | $60.6M | N/A | $41.6M | N/A | $22.5M |
| SG&A Expenses | $12.2M-24.0% | $16.0M | N/A | $15.3M | N/A | $8.1M |
| Operating Income | -$57.7M+24.7% | -$76.6M | N/A | -$56.9M | N/A | -$30.6M |
| Interest Expense | $747K | $0 | N/A | N/A | N/A | N/A |
| Income Tax | $0-100.0% | $53K | N/A | N/A | N/A | N/A |
| Net Income | -$56.8M+21.8% | -$72.5M | N/A | -$53.0M | N/A | -$29.3M |
| EPS (Diluted) | $-0.35+22.2% | $-0.45 | N/A | $-1.14 | N/A | $-1.06 |
NMRA Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Total Assets | $177.8M-43.9% | $317.0M-36.1% | $496.2M-8.9% | $544.7M+27.8% | $426.2M | N/A |
| Current Assets | $177.1M-43.6% | $314.1M-34.3% | $478.3M-9.0% | $525.7M+35.5% | $388.0M | N/A |
| Cash & Equivalents | $129.1M-9.2% | $142.1M-62.0% | $374.0M-9.3% | $412.3M+71.1% | $240.9M-4.6% | $252.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $45.7M+52.7% | $29.9M+10.3% | $27.1M-15.4% | $32.1M-96.3% | $873.1M | N/A |
| Current Liabilities | $25.8M-13.5% | $29.9M+19.0% | $25.1M-13.8% | $29.1M+22.9% | $23.7M | N/A |
| Long-Term Debt | $19.6M | $0 | N/A | N/A | N/A | N/A |
| Total Equity | $132.2M-54.0% | $287.1M-38.8% | $469.1M-8.5% | $512.7M+214.7% | -$446.9M-5.9% | -$422.0M |
| Retained Earnings | -$1.1B-18.7% | -$947.2M-34.7% | -$703.4M-18.3% | -$594.7M-27.2% | -$467.5M | N/A |
NMRA Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$46.6M+7.4% | -$50.3M+2.1% | -$51.4M-7.7% | -$47.8M-57.3% | -$30.4M | N/A |
| Capital Expenditures | N/A | N/A | $44K+18.9% | $37K+60.9% | $23K | N/A |
| Free Cash Flow | N/A | N/A | -$51.5M-7.7% | -$47.8M-57.3% | -$30.4M | N/A |
| Investing Cash Flow | $51.3M+151.9% | -$98.8M-822.4% | $13.7M-42.6% | $23.8M+396.6% | -$8.0M | N/A |
| Financing Cash Flow | -$136K-100.9% | $15.6M+3337.6% | -$481K-100.2% | $232.0M+764.7% | $26.8M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
NMRA Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -31.9%-11.3pp | -20.6% | N/A | -9.7% | N/A | N/A |
| Current Ratio | 6.85-3.7 | 10.51-8.5 | 19.05+1.0 | 18.05+1.7 | 16.37 | N/A |
| Debt-to-Equity | 0.15+0.1 | 0.00-0.1 | 0.060.0 | 0.06+2.0 | -1.95 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Neumora Therapeutics Inc profitable?
No, Neumora Therapeutics Inc (NMRA) reported a net income of -$243.8M in fiscal year 2024.
What is Neumora Therapeutics Inc's earnings per share (EPS)?
Neumora Therapeutics Inc (NMRA) reported diluted earnings per share of $-1.53 for fiscal year 2024. This represents a 57.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Neumora Therapeutics Inc's EBITDA?
Neumora Therapeutics Inc (NMRA) had EBITDA of -$262.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Neumora Therapeutics Inc have?
As of fiscal year 2024, Neumora Therapeutics Inc (NMRA) had $142.1M in cash and equivalents against $0 in long-term debt.
What is Neumora Therapeutics Inc's operating cash flow?
Neumora Therapeutics Inc (NMRA) generated -$182.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Neumora Therapeutics Inc's total assets?
Neumora Therapeutics Inc (NMRA) had $317.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Neumora Therapeutics Inc spend on research and development?
Neumora Therapeutics Inc (NMRA) invested $200.9M in research and development during fiscal year 2024.
How many shares does Neumora Therapeutics Inc have outstanding?
Neumora Therapeutics Inc (NMRA) had 162M shares outstanding as of fiscal year 2024.
What is Neumora Therapeutics Inc's current ratio?
Neumora Therapeutics Inc (NMRA) had a current ratio of 10.51 as of fiscal year 2024, which is generally considered healthy.
What is Neumora Therapeutics Inc's debt-to-equity ratio?
Neumora Therapeutics Inc (NMRA) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neumora Therapeutics Inc's return on assets (ROA)?
Neumora Therapeutics Inc (NMRA) had a return on assets of -76.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Neumora Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Neumora Therapeutics Inc (NMRA) had $142.1M in cash against an annual operating cash burn of $182.9M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Neumora Therapeutics Inc's Piotroski F-Score?
Neumora Therapeutics Inc (NMRA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neumora Therapeutics Inc's earnings high quality?
Neumora Therapeutics Inc (NMRA) has an earnings quality ratio of 0.75x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.